Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid growth in GWAS datasets, we extend the original work using updated data, test whether genetic evidence predicts future successes and introduce statistical models adjusting for target and indication-level properties. Our work confirms drugs with genetically supported targets were more likely to be successful in Phases II and III. When causal genes are clear (Mendelian traits and GWAS associations linked to coding variants), we find the use of human genetic evidence increases approval by greater than two-fold, and, for Mendelian associations, the positive association holds prospectively. Our findings suggest investments into genomics and genetics are likely to be beneficial to companies deploying this strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig 1 Estimated effect of evidence from human genetic studies on the probability of advancing in clinical development. A: Partitioning Pharmaprojects, OMIM, and GWAS Catalog into training data available to Nelson et al. 2015 and validation sets. We use validation set Pipeline Progression, consisting of target-indication pairs assigned a clinical phase in 2013, to determine whether gene target-indication pairs with genetic evidence were more likely to advance to the next pipeline phase from 2013-2018. Pharmaprojects target-indication pairs absent from or assigned an unknown clinical phase in the Nelson et al. dataset form the New Pipeline replication set. Pharmaprojects target-indication pairs approved prior to 2013 or with unknown phase in our dataset are not part of any replication set. B: Our estimates of the effect of genetic evidence on gene target-indication pair progression compared to values reported by Nelson et al. 2015 [3] in validation sets New Pipeline (drugs and indications > 2013, 2013 inactive drugs) New Genetic (only new genetic information > 2013) Pipeline Progression, and in the full updated dataset (Full Data). Estimates falling close to the identity line (shown in black) are consistent between the two analyses.](https://figures.cochat.ai/paper-figures/fbfe5599a9364dd7aab42f07a9e12b6a/are-drug-targets-with-genetic-support-twice-as-likely-to-be-approved-revised-figure-1.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is supported by drug candidates with genetically supported targets being significantly more likely to progress through phased clinical trials (9, 10).”
From Identification of human gene research articles with wrongly identified nucleotide sequences (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
The GTEx Consortium, Ardlie, K. G., Deluca, D. S., Segrè, A. V., Sullivan, T. J., Young, T. R., Gelfand, E. T., Trowbridge, C. A., Maller, J. B., Tukiainen, T., et al. (2015) · Science · doi:10.1126/science.1262110 · Cited by 5,062
An Information-Theoretic Definition of Similarity
Lin, D. (1998) · International Conference on Machine Learning · Cited by 4,697
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536
Watanabe, S. (2010) · arXiv (Cornell University) · doi:10.48550/arxiv.1004.2316 · Cited by 2,226
Research works printed but not linked: 1
- J MacArthur, 2016, The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog), Nucleic Acids Research, 45, D896, 10.1093/nar/gkw1133 · DOI · Paper page
Cited by
Items 101–200 of 648
Haglund, A., Zuber, V., Abouzeid, M., Yang, Y., Ko, J. H., Wiemann, L., Otero‐Jimenez, M., Muhammed, L., Feleke, R., Nott, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02050-9 · Cited by 57
Integrative analysis of 3604 GWAS reveals multiple novel cell type-specific regulatory associations
Breeze, C. E., Haugen, E., Reynolds, A. P., Teschendorff, A. E., van Dongen, J., Lan, Q., Rothman, N., Bourque, G., Dunham, I., Beck, S., et al. (2022) · Genome biology · doi:10.1186/s13059-021-02560-3 · Cited by 49
Genetic and environmental risk factors for asthma: towards prevention
Koppelman, G. H., Pino-Yanes, M. D. M., Melén, E., Powell, P., Bracke, K. R., Celedon, J. C., & Brusselle, G. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00256-5 · Cited by 54
Perspectives on Drug Repurposing
Schcolnik‐Cabrera, A., Juárez-López, D., & Dueñas‐González, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831141337 · Cited by 47
Assigning function to SNPs: Considerations when interpreting genetic variation
Fadason, T., Farrow, S. L., Gokuladhas, S., Golovina, E., Nyaga, D. M., O'Sullivan, J. M., & Schierding, W. S. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.08.008 · Cited by 51
Harnessing the potential of machine learning and artificial intelligence for dementia research
Ranson, J. M., Bucholc, M., Lyall, D. M., Newby, D., Winchester, L. M., Oxtoby, N. P., Veldsman, M., Rittman, T., Marzi, S. J., Skene, N., et al. (2023) · Brain Informatics · doi:10.1186/s40708-022-00183-3 · Cited by 48
Multi-layered genetic approaches to identify approved drug targets
Sadler, M. C., Auwerx, C., Deelen, P., & Kutalik, Z. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100341 · Cited by 55
Expanding causal genes for Parkinson’s disease via multi-omics analysis
Gu, X., Su, W., Dou, M., Jiang, Z., Duan, Q., Yin, K., Cao, B., Wang, Y., Li, G., & Chen, Y. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00591-0 · Cited by 46
Immune modulation to treat Alzheimer’s disease
Duggan, M. R., Morgan, D., Price, B. R., Rajbanshi, B., Martín‐Peña, A., Tansey, M. G., & Walker, K. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00828-x · Cited by 49
Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension
Ulrich, A., Wharton, J., Thayer, T. E., Świetlik, E. M., Assad, T. R., Desai, A. A., Gräf, S., Harbaum, L., Humbert, M. J. C., Morrell, N. W., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01486-2019 · Cited by 44
Human inducible pluripotent stem cells: Realization of initial promise in drug discovery
Kleiman, R. J., & Engle, S. J. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.08.002 · Cited by 43
Gautam, V., Gaurav, A., Masand, N., Lee, V. S., & Patil, V. M. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10489-3 · Cited by 44
Ray, A., Alabarse, P. V. G., Malik, R., Sargurupremraj, M., Bernhagen, J., Dichgans, M., Baumeister, S., & Georgakis, M. K. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.06.001 · Cited by 42
Deaton, A. M., Parker, M. M., Ward, L. D., Flynn-Carroll, A. O., BonDurant, L., Hinkle, G., Akbari, P., Lotta, L. A., Regeneron Genetics Center, RGC Management and Leadership Team, et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99091-5 · Cited by 34
Examining the shared etiology of psychopathology with genome-wide association studies
Mallard, T. T., Grotzinger, A. D., & Smoller, J. W. (2023) · Physiological Reviews · doi:10.1152/physrev.00016.2022 · Cited by 40
A comparison of computational methods for expression forecasting
Kernfeld, E. M., Yang, Y., Weinstock, J. S., Battle, A. J., & Cahan, P. (2025) · Genome biology · doi:10.1186/s13059-025-03840-y · Cited by 51
Lee, J., Fernández‐Cadenas, I., & Lindgren, A. G. (2021) · Stroke · doi:10.1161/strokeaha.121.032622 · Cited by 44
Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics
Montero‐Melendez, T., Boesen, T. P., & Jonassen, T. E. N. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101603 · Cited by 38
Wingo, T. S., Gerasimov, E. S., Liu, Y., Duong, D. M., Vattathil, S., Lori, A., Gockley, J., Breen, M. S., Maihofer, A. X., Nievergelt, C. M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01544-4 · Cited by 41
Winkler, T. W., Rasheed, H., Teumer, A., Gorski, M., Rowan, B. X., Stanzick, K. J., Thomas, L. F., Tin, A., Hoppmann, A., Chu, A. Y., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03448-z · Cited by 39
Identification of human gene research articles with wrongly identified nucleotide sequences
Park, Y., West, R. A., Pathmendra, P., Favier, B., Stoeger, T., Capes-Davis, A., Cabanac, G., Labbé, C., & Byrne, J. A. (2022) · Life Science Alliance · doi:10.26508/lsa.202101203 · Cited by 37
MendelVar: gene prioritization at GWAS loci using phenotypic enrichment of Mendelian disease genes
Sobczyk, M., Gaunt, T. R., & Paternoster, L. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa1096 · Cited by 40
Osteoarthritis year in review 2024: Genetics, genomics, and epigenetics
Boer, C. G. (2024) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2024.10.014 · Cited by 38
Turning genome-wide association study findings into opportunities for drug repositioning
Lau, A., & So, H. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.06.015 · Cited by 39
Shared genetic architecture across psychiatric disorders
Grotzinger, A. D. (2021) · Psychological Medicine · doi:10.1017/s0033291721000829 · Cited by 46
Priority index: database of genetic targets in immune-mediated disease
Fang, H., & Knight, J. C. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab994 · Cited by 39
McDonagh, E. M., Trynka, G., McCarthy, M. I., Holzinger, E. R., Shameer, K., Nakić, N., Hu, X., Cornu, H., Dunham, I., & Hulcoop, D. G. (2024) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-102523-103838 · Cited by 38
CRISPR Meets Zebrafish: Accelerating the Discovery of New Therapeutic Targets
Rubbini, D., Cornet, C., Terriente, J., & Donato, V. D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220926920 · Cited by 37
Bao, C., Wang, H., & Fang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.758440 · Cited by 40
Multi-Ancestry Meta-Analysis yields novel genetic discoveries and ancestry-specific associations
Turley, P., Martin, A. R., Goldman, G., Li, H., Kanai, M., Walters, R. K., Jala, J. B., Lin, K., Millwood, I. Y., Carey, C. E., et al. (2021) · doi:10.1101/2021.04.23.441003 · Cited by 35
Mortberg, M. A., Vallabh, S. M., & Minikel, E. V. (2022) · Scientific Reports · doi:10.1038/s41598-022-21820-1 · Cited by 35
Multitrait GWAS to connect disease variants and biological mechanisms
Julienne, H., Laville, V., McCaw, Z. R., He, Z., Guillemot, V., Lasry, C., Ziyatdinov, A., Nerin, C., Vaysse, A., Lechat, P., et al. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009713 · Cited by 48
Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications
Duffy, Á., Petrazzini, B. O., Stein, D. F., Park, J. K., Forrest, I. S., Gibson, K., Vy, H. M. T., Chen, R. K., Márquez‐Luna, C., Mort, M. E., et al. (2024) · Nature Genetics · doi:10.1038/s41588-023-01609-2 · Cited by 48
Krill-Burger, J. M., Dempster, J. M., Borah, A. A., Paolella, B. R., Root, D. E., Golub, T. R., Boehm, J. S., Hahn, W. C., McFarland, J. M., Vázquez, F., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03020-w · Cited by 38
Genetic and Epigenetic Landscape for Drug Development in Polycystic Ovary Syndrome
Chen, Y., Wang, G., Chen, J., Wang, C., Dong, X., Chang, H., Yuan, S., Zhao, Y., & Mu, L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae002 · Cited by 41
Krahn, A. I., Wells, C. I., Drewry, D. H., Beitel, L. K., Durcan, T. M., & Axtman, A. D. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00176 · Cited by 36
Choi, D. E., Shin, J. W., Zeng, S., Hong, E. P., Jang, J.-H., Loupe, J. M., Wheeler, V. C., Stutzman, H. E., Kleinstiver, B., & Lee, J. (2024) · eLife · doi:10.7554/elife.89782 · Cited by 36
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 34
Polygenic Score Models for Alzheimer’s Disease: From Research to Clinical Applications
Zhou, X., Li, Y. Y. T., Fu, A. K. Y., & Ip, N. Y. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.650220 · Cited by 35
Rare versus common diseases: a false dichotomy in precision medicine
Chung, B. H., Chau, J. F. T., & Wong, G. K. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00176-x · Cited by 37
Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases
Kiiskinen, T., Helkkula, P., Krebs, K., Karjalainen, J. M., Saarentaus, E., Mars, N., Lehistö, A., Zhou, W., Cordioli, M., Jukarainen, S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02122-5 · Cited by 33
CRISPR screens identify gene targets at breast cancer risk loci
Tuano, N. K., Beesley, J., Manning, M., Shi, W., Perlaza-Jimenez, L., Malaver-Ortega, L. F., Paynter, J. M., Black, D., Civitarese, A., McCue, K., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-02898-w · Cited by 30
Castaldi, P. J., Abood, A., Farber, C. R., & Sheynkman, G. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac196 · Cited by 41
Farrell, S. F., Kho, P. F., Lundberg, M., Campos, A. I., Rentería, M. E., de Zoete, R. M. J., Sterling, M. M., Ngô, T. T., & Cuéllar-Partida, G. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.10.005 · Cited by 30
Zhou, S., Sosina, O. A., Bovijn, J., Laurent, L., Sharma, V., Akbari, P., Forgetta, V., Jiang, L., Kosmicki, J. A., Banerjee, N., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01444-5 · Cited by 32
Schuermans, N., Chehadeh, S. E., Hemelsoet, D., Gautheron, J., Vantyghem, M., Nouioua, S., Tazir, M., Vigouroux, C., Auclair, M., Bogaert, E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01535-3 · Cited by 31
From the Genetics of Ankylosing Spondylitis to New Biology and Drug Target Discovery
Zaarour, N., Li, Y., Hui, S., Paul, B., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624632 · Cited by 38
(2024) · doi:10.1038/s41592-024-02409-0 · Cited by 29
Kwon, S., Safer, J., Nguyen, D. T., Hoksza, D., May, P., Arbesfeld, J. A., Rubin, A. F., Campbell, A. J., Burgin, A., & Iqbal, S. (2024) · doi:10.1101/2024.01.02.573913 · Cited by 29
Effect of longevity genetic variants on the molecular aging rate
Gurinovich, A., Song, Z., Zhang, W., Federico, A. N., Monti, S., Andersen, S. L., Jennings, L. L., Glass, D. J., Barzilai, N., Milman, S., et al. (2021) · GeroScience · doi:10.1007/s11357-021-00376-4 · Cited by 31
Gaining insight into metabolic diseases from human genetic discoveries
Claussnitzer, M., & Suszták, K. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.07.005 · Cited by 30
The legacy of the Human Genome Project
Rood, J., & Regev, A. (2021) · Science · doi:10.1126/science.abl5403 · Cited by 32
Prioritising genetic findings for drug target identification and validation
Hukerikar, N., Hingorani, A. D., Asselbergs, F. W., Finan, C., & Schmidt, A. F. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117462 · Cited by 28
Kho, P., Wang, X.-M., Cuéllar-Partida, G., Dörk, T., Goode, E., Lambrechts, D., Scott, R., Spurdle, A., O'Mara, T., & Glubb, D. M. (2021) · Communications Biology · doi:10.1038/s42003-021-02745-3 · Cited by 27
Rivier, C. A., Renedo, D. B., de Havenon, A., Sunmonu, N. A., Gill, T. M., Payabvash, S., Sheth, K. N., & Falcone, G. J. (2023) · Neurology · doi:10.1212/wnl.0000000000208010 · Cited by 29
Future prospects for human genetics and genomics in drug discovery
Ghoussaini, M., Nelson, M. R., & Dunham, I. (2023) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2023.102568 · Cited by 30
Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease
Pengo, M., & Squitieri, F. (2024) · Genes · doi:10.3390/genes15060807 · Cited by 32
Identifying therapeutic drug targets using bidirectional effect genes
Estrada, K., Froelich, S., Wuster, A., Bauer, C. R., Sterling, T., Clark, W. T., Ru, Y., Trinidad, M., Nguyen, H. P., Luu, A. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21843-8 · Cited by 25
Advancing drug discovery using the power of the human genome
Heilbron, K., Mozaffari, S. V., Vacic, V., Yue, P., Wang, W., Shi, J., Jubb, A. M., Pitts, S. J., & Wang, X. (2021) · The Journal of Pathology · doi:10.1002/path.5664 · Cited by 28
FAM13A as potential therapeutic target in modulating TGF-β-induced airway tissue remodeling in COPD
Tam, A., Leclair, P., Li, L. V., Yang, C. X., Li, X., Witzigmann, D., Kulkarni, J. A., Hackett, T., Dorscheid, D. R., Singhera, G. K., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00477.2020 · Cited by 26
Precision medicine for asthma treatment: Unlocking the potential of the epigenome and microbiome
Pérez-García, J., Cárdenas, A., Lorenzo-Díaz, F., & Pino-Yanes, M. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.06.010 · Cited by 30
Single-cell-led drug repurposing for Alzheimer’s disease
Parolo, S., Mariotti, F., Bora, P., Carboni, L., & Domenici, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-27420-x · Cited by 28
Genetic Susceptibility to Pneumonia: A GWAS Meta-Analysis Between the UK Biobank and FinnGen
Campos, A. I., Kho, P. F., Vazquez‐Prada, K. X., García‐Marín, L. M., Martin, N. G., Cuéllar-Partida, G., & Rentería, M. E. (2021) · Twin Research and Human Genetics · doi:10.1017/thg.2021.27 · Cited by 27
Proteomics and Epidemiological Models of Human Aging
Ubaida‐Mohien, C., Moaddel, R., Moore, A. Z., Kuo, P., Faghri, F., Tharakan, R., Tanaka, T., Nalls, M. A., & Ferrucci, L. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.674013 · Cited by 24
Precision Medicine Approaches to Vascular Disease
Miller, C. L., Kontorovich, A., Hao, K., Ma, L., Iyegbe, C. O., Björkegren, J., & Kovacic, J. C. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.001 · Cited by 24
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics
Lam, M., Chen, C., Ge, T., Xia, Y., Hill, D. W., Trampush, J. W., Yu, J., Knowles, E., Davies, G., Stahl, E. A., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01023-4 · Cited by 26
Ogishima, S., Nagaie, S., Mizuno, S., Ishiwata, R., Iida, K., Shimokawa, K., Takai‐Igarashi, T., Nakamura, N., Nagase, S., Nakamura, T., et al. (2021) · Human Genome Variation · doi:10.1038/s41439-021-00175-5 · Cited by 24
Drug re‐engineering and repurposing: A significant and rapid approach to tuberculosis drug discovery
Reddy, D. S., Sinha, A., Kumar, A., & Saini, V. K. (2022) · Archiv der Pharmazie · doi:10.1002/ardp.202200214 · Cited by 23
The Interface of Therapeutics and Genomics in Cardiovascular Medicine
Magavern, E. F., Kaski, J. C., Turner, R. M., Janmohamed, A., Borry, P., & Pirmohamed, M. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07149-3 · Cited by 25
Mendelian randomization of circulating proteome identifies actionable targets in heart failure
Moncla, L.-H. M., Mathieu, S., Sylla, M. S., Bossé, Y., Thériault, S., Arsenault, B. J., & Mathieu, P. (2022) · BMC Genomics · doi:10.1186/s12864-022-08811-2 · Cited by 25
Pividori, M., Lu, S., Li, B., Su, C., Johnson, M. E., Wei, W., Feng, Q., Namjou, B., Kiryluk, K., Kullo, I. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41057-4 · Cited by 29
Estimating the impact of single-cell RNA sequencing of human tissues on drug target validationPreprint
Dann, E., Teeple, E. A., Elmentaite, R., Meyer, K. B., Gaglia, G., Nestle, F. O., Savova, V., de Rinaldis, E., & Teichmann, S. A. (2024) · medRxiv · doi:10.1101/2024.04.04.24305313 · Cited by 24
Konuma, T., Ogawa, K., & Okada, Y. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab049 · Cited by 22
Artificial Intelligence in Oncology Drug Discovery and Development
Cassidy, J. W., & Taylor, B. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88376 · Cited by 24
Friedman, C. E., Cheetham, S. W., Negi, S., Mills, R. J., Ogawa, M., Redd, M. A., Chiu, H. S., Shen, S., Sun, Y., Mizikovsky, D., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.11.012 · Cited by 25
Zhang, Z., Fang, T., Chen, L., Ji, F., & Chen, J. (2024) · American Journal of Cancer Research · doi:10.62347/bczw1355 · Cited by 24
Vorstman, J. A. S., & Scherer, S. W. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.017 · Cited by 21
Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery
Krebs, K., & Milani, L. A. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051421-111324 · Cited by 20
Khan, Z., Jung, M., Crow, M., Mohindra, R., Maiya, V., Kaminker, J. S., Hackos, D. H., Chandler, G. S., McCarthy, M. I., & Bhangale, T. (2023) · Genome Medicine · doi:10.1186/s13073-023-01193-4 · Cited by 22
eQTLs identify regulatory networks and drivers of variation in the individual response to sepsis
Burnham, K. L., Milind, N., Lee, W., Kwok, A. J., Cano-Gamez, K., Mi, Y., Geoghegan, C. G., Zhang, P., Addison, J., Galley, H. F., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100587 · Cited by 24
Stikker, B., Trap, L., Sedaghati-khayat, B., de Bruijn, M. J. W., van IJcken, W. F. J., de Roos, E. W., Ikram, M. A., Hendriks, R. W., Brusselle, G., van Rooij, J., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.02059-2023 · Cited by 21
Thorsteinsson, H. S., Baukmann, H. A., Sveinsdóttir, H. S., Halldórsdóttir, D. Þ., Grzymala, B., Hillman, C., Rolfe-Tarrant, J., Parker, M. O., Cope, J. L., Ravarani, C. N. J., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02062-x · Cited by 24
Expanding the drug discovery space with predicted metabolite–target interactions
Nuzzo, A., Saha, S., Berg, E. L., Jayawickreme, C. K., Tocker, J. E., & Brown, J. R. (2021) · Communications Biology · doi:10.1038/s42003-021-01822-x · Cited by 23
The grand challenge of discovering new cardiovascular drugs
Hong, C. C. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1027401 · Cited by 21
Long, E., Wan, P., Chen, Q., Lu, Z., & Choi, J. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100320 · Cited by 23
Alvarado, C. X., Makarious, M. B., Weller, C. A., Vitale, D., Koretsky, M. J., Bandrés‐Ciga, S., Iwaki, H., Levine, K. S., Singleton, A., Faghri, F., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.12.006 · Cited by 19
Transcriptome‐Wide Association Studies (TWAS): Methodologies, Applications, and Challenges
Evans, P. D., Nagai, T. H., Konkashbaev, A. I., Zhou, D., Knapik, E. W., & Gamazon, E. R. (2024) · Current Protocols · doi:10.1002/cpz1.981 · Cited by 20
Hillary, R. F., Gadd, D. A., Kuncheva, Z., Mangelis, T., Lin, T.-C., Ferber, K. L., McLaughlin, H., Runz, H., Biogen Biobank Team, Marshall, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51744-5 · Cited by 20
Stroke Genetics: Turning Discoveries into Clinical Applications
Dichgans, M., Beaufort, N., Debette, S., & Anderson, C. D. (2021) · Stroke · doi:10.1161/strokeaha.121.032616 · Cited by 21
Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias
Yu, L., Boyle, P. A., Wingo, A. P., Yang, J., Wang, T., Buchman, A. S., Wingo, T. S., Seyfried, N. T., Levey, A. I., Jager, P. L. D., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013252 · Cited by 21
Giblin, K. A., Basili, D., Afzal, A. M., Rosenbrier-Ribeiro, L., Greene, N., Barrett, I., Hughes, S. J., & Bender, A. (2021) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00311 · Cited by 18
Functional analysis of cancer-associated germline risk variants
Kellman, L. N., Neela, P. H., Srinivasan, S., Siprashvili, Z., Shanderson, R. L., Hong, A. W., Rao, D. S., Porter, D. F., Reynolds, D. L., Meyers, R. M., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02070-5 · Cited by 22
Prioritizing Parkinson’s disease risk genes in genome-wide association loci
Lange, L. M., Cerquera‐Cleves, C., Schipper, M., Panagiotaropoulou, G., Braun, A., Kraft, J., Awasthi, S., Bell, N., Posthuma, D., Ripke, S., et al. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00933-0 · Cited by 21
Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans
Lai, D., Schwantes-An, T.-H. L., Abreu, M., Chan, G., HESSELBROCK, V. M., Kamarajan, C., Liu, Y., Meyers, J. L., Nürnberger, J. I., Plawecki, M. H., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02029-2 · Cited by 19
Eskandari, S. K., da Costa, M. G., Faria, B., Petr, V., Azzi, J. R., Berger, S. P., Seelen, M. A., Damman, J. J., & Poppelaars, F. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17212 · Cited by 18
Gu, X., Dou, M., Su, W., Jiang, Z., Duan, Q., Cao, B., & Chen, Y. (2022) · BMC Medicine · doi:10.1186/s12916-022-02679-5 · Cited by 23
Malik, M. A., Faraone, S. V., Michoel, T., & Haavik, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108530 · Cited by 19
Dementia prevention: the Mendelian randomisation perspective
Anderson, E. L., Davies, N. M., Korologou‐Linden, R., & Kivimäki, M. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-332293 · Cited by 25
Richard, D. J., Capellini, T. D., & Diekman, B. O. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00574.2022 · Cited by 18
GeneDisco: A Benchmark for Experimental Design in Drug DiscoveryPreprint
Mehrjou, A., Soleymani, A., Jesson, A., Notin, P., Gal, Y., Bauer, S., & Schwab, P. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2110.11875 · Cited by 26
Metadata
- Authors
- King, E. A., Davis, J. W., & Degner, J. F.
- Affiliations
- AbbVie (United States) (US)
- Corresponding author
- King, Emily A.
- Venue
- PLOS Genetics
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-12
- Volume
- 15
- Issue
- 12
- Pages
- e1008489
- ISSN
- 1553-7390 (ISSN-L)
- 1553-7404
- PMC
- PMC6907751
- OpenAlex
- W2995245946
- Cited by
- 649
- References
- 40
- Citations by year
- 2026: 71 · 2025: 97 · 2024: 132 · 2023: 118 · 2022: 92 · 2021: 85 · 2020: 47 · 2019: 6
- FWCI
- 34.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Genetics (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- drug approval, therapeutic target, genetic evidence, drug development pipeline, new chemical entities, monogenic disorders, genome-wide association study, coding variants, drug development investment
- MeSH terms
- Pharmacogenomic Variants, Humans, Phenotype, Models, Statistical, Drug Approval, Genetic Predisposition to Disease, Genomics, Databases, Genetic, Quantitative Trait Loci, Genome-Wide Association Study, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.